Upstream Bioprocess Development for Adenovirus Vector
Viral vectors are widely used in cell therapy, gene therapy, and viral vaccines by carrying specific genes into target cells, to achieve the purpose of modifying genes and expressing proteins, thereby treating diseases. Creative Biolabs has always provided quality upstream services for customers' adenovirus development. From the retrieval of literature/patents to the transformation of vector genes, tropism design and stability testing, we guarantee the safety and stability of your downstream experiments with world-leading technology. No matter what difficulties you have encountered in the relevant research work, you can contact us to get your customized service.
Overview of Adenovirus Vector Development
The development of adenovirus vectors can be generally divided into several stages and different development platforms. In general, materials needed for the development of therapeutic viral vectors should be prepared first, such as plasmids that hold helper virus functions and therapeutic genes, and cell lines used to make vectors. Viral vectors are then produced using transiently transfected or constructed stable cell lines. The manufacture of viral vectors by transfection is flexible and efficient, but at a higher cost, and may require additional purification steps to remove plasmid and cellular DNA, and thus is not suitable for large-scale production. Stable cell lines can significantly increase the efficiency of viral vector production, but the development of cell lines is a hard work that requires numerous time and effort, and is not recommended for use in the experimental phase.
Figure 1. Upstream bioprocess development for adenovirus vector.
Optimization of the Development Process of Adenovirus Vector
In order to achieve efficient, reproducible and scalable production of adenoviral vectors, expressing the largest amount of adenovirus vectors in a single cell will be the primary goal of our work. While maintaining maximum yield, the cell density for vector production is increased and the total yield of adenovirus is increased. The second goal of optimizing adenoviral vectors is to ensure the quality requirements of the final product. For replication-deficient recombinant adenoviral vectors, although it can safely and efficiently deliver therapeutic genes to target cells without replicating their own viral genome, some cancer treatments require adenoviral vectors to maintain their ability to replicate. This requires us to adjust our R&D strategy according to customers' requirements.
Creative Biolabs has always believed that an understanding of the physiological environment and metabolic processes of host cell lines and an in-depth study of the interaction mechanisms between viral vectors and host cells are the most important advantages of our successful development of recombinant adenoviral vectors. Our scientists conduct small-scale studies on the kinetics of metabolic and viral infections in different cell lines to determine optimal culture conditions. We will also develop monitoring tools to monitor the physiological parameters of the culture and control the expression process. If you have any questions or have any difficulties, you can contact us by email or send us an inquiry to find a complete solution.
